P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS

Documenti analoghi

• Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
  di: Srdan Verstovsek, et al.
  Pubblicazione: (2016-12-01)
• Treatment Strategies Used in Treating Myelofibrosis: State of the Art
  di: Massimo Martino, et al.
  Pubblicazione: (2024-10-01)
• Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy
  di: Sophia S. Lee, et al.
  Pubblicazione: (2021-08-01)
• Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
  di: Srdan Verstovsek, et al.
  Pubblicazione: (2023-07-01)
• JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
  di: Andrew T. Kuykendall, et al.
  Pubblicazione: (2021-08-01)